Should You Buy Alumis Inc (ALMS) Today? Analysis, Price Targets, and 2026 Outlook.
Analysis Updated At
2026/01/28
Buy now (good buy for a long-term investor), because the trend is bullish, options positioning is strongly call-skewed, insiders are buying aggressively, and Wall Street targets were sharply raised after strong Phase 3 results—suggesting the market is re-rating the story upward. With the investor being a beginner and long-term oriented, this fits best as a growth/speculative biotech position rather than a core, but the current setup still supports entering at today’s price rather than waiting.
Technical Analysis
Trend is bullish. Price (~26.02 pre-market) sits above rising moving averages (SMA_5 > SMA_20 > SMA_200), confirming an uptrend. MACD histogram is positive (0.327) but contracting, implying upside momentum is still present but cooling after a run. RSI(6) at ~69.2 is near overbought territory, so short-term churn/pullbacks are possible even within a bullish trend. Key levels: Support near pivot ~24.14 (then ~21.47). Resistance at R1 ~26.82 (near-term ceiling) then R2 ~28.47. Overall: uptrend intact; entry here is reasonable for an impatient buyer, with the nearest technical risk defined below ~24.14.
Analyst Ratings and Price Target Trends
Recent trend is sharply more bullish. From 2026-01-06 through 2026-01-21, multiple firms raised targets and reiterated Buy/Outperform/Overweight after positive Phase 3 data: Oppenheimer to $50 (from $25), H.C. Wainwright to $40 (from $20), Wells Fargo to $39 (from $17), Morgan Stanley to $33 (from $22), Guggenheim to $32 (from $18), Leerink to $32 (from $20), and Chardan initiated Buy with a $37 target. Wall Street pros view: (Pros) best-in-class TYK2 profile potential, Phase 3 success de-risks the lead program, large autoimmune market opportunity. (Cons) valuation and future moves hinge on continued execution (regulatory/commercial) and biotech event risk; current financials do not yet reflect a commercial-stage company.
Intellectia Proprietary Trading Signals
- [AI Stock Picker](module://ai_stock_pick): No signal on given stock today.
- [SwingMax](module://swingmax): No signal on given stock recently.
Influential/political activity: No recent congress trading data available. Hedge funds: neutral over the last quarter. Insiders: buying strongly (up ~586% last month).
Wall Street analysts forecast ALMS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALMS is 37.67 USD with a low forecast of 32 USD and a high forecast of 50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Wall Street analysts forecast ALMS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALMS is 37.67 USD with a low forecast of 32 USD and a high forecast of 50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Current: 27.710
Current: 27.710
